Redwood AI Corp. Partners with Resilience Biosciences to Advance AI-Driven Drug Discovery for Non-Opioid Therapeutics

Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) has entered into a collaboration with Resilience Biosciences Inc. to leverage artificial intelligence for small-molecule drug development, specifically targeting non-opioid therapeutic programs. The partnership aims to improve the efficiency of identifying, analyzing, and advancing potential drug candidates through computational chemistry and cheminformatics.

Under the agreement, Redwood AI will apply its expertise in computational chemistry, cheminformatics, and synthetic route design to support Resilience's drug discovery workflows. These include derivative generation, patentability and freedom-to-operate analysis, and retrosynthetic planning—all intended to accelerate early-stage development. The focus on non-opioid pain therapies addresses a critical need for alternatives to opioids, which carry risks of addiction and overdose.

“Our collaboration with Resilience Biosciences represents a significant step in applying AI to solve complex chemistry challenges in drug discovery,” said a Redwood AI spokesperson. “By combining our computational tools with Resilience’s therapeutic expertise, we aim to streamline the path from concept to candidate.”

The announcement underscores the increasing adoption of AI in pharmaceutical R&D, where machine learning models can predict molecular properties, optimize synthesis routes, and assess patent landscapes faster than traditional methods. This collaboration could serve as a model for future partnerships between AI-focused firms and biotech companies seeking to reduce development timelines and costs.

For more information about Redwood AI and its technology, visit https://redwoodai.com/. The full press release is available at https://ibn.fm/xCQEe.